Royalty Pharma plc (NASDAQ:RPRX) went down by -3.66% from its latest closing price compared to the recent 1-year high of $56.50. The company’s stock price has collected 1.00% of gains in the last five trading sessions. Press Release reported on 01/08/21 that Royalty Pharma Announces 13% Dividend Increase
Is It Worth Investing in Royalty Pharma plc (NASDAQ :RPRX) Right Now?
Opinions of the stock are interesting as 4 analysts out of 9 who provided ratings for Royalty Pharma plc declared the stock was a “buy,” while 0 rated the stock as “overweight,” 5 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $51.88, which is $2.7 above the current price. RPRX currently public float of 83.12M and currently shorts hold a 16.00% ratio of that float. Today, the average trading volume of RPRX was 2.61M shares.
RPRX’s Market Performance
RPRX stocks went up by 1.00% for the week, with a monthly jump of 9.38% and a quarterly performance of 11.33%. The volatility ratio for the week stands at 4.88% while the volatility levels for the past 30 days are set at 4.89% for Royalty Pharma plc. The simple moving average for the period of the last 20 days is 4.41% for RPRX stocks with a simple moving average of 13.77% for the last 200 days.
Analysts’ Opinion of RPRX
Many brokerage firms have already submitted their reports for RPRX stocks, with UBS repeating the rating for RPRX by listing it as a “Buy.” The predicted price for RPRX in the upcoming period, according to UBS is $51 based on the research report published on November 09th of the previous year 2020.
UBS gave a rating of “Neutral” to RPRX, setting the target price at $52 in the report published on July 13th of the previous year.
RPRX Trading at 13.44% from the 50-Day Moving Average
After a stumble in the market that brought RPRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.50% of loss for the given period.
Volatility was left at 4.89%, however, over the last 30 days, the volatility rate increased by 4.88%, as shares surge +16.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +36.05% upper at present.
During the last 5 trading sessions, RPRX rose by +1.00%, in comparison to the 20-day moving average, which settled at $47.70. In addition, Royalty Pharma plc saw -1.22% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at RPRX starting from ADAGE CAPITAL PARTNERS GP, L.L, who sale 101,050 shares at the price of $44.02 back on Dec 18. After this action, ADAGE CAPITAL PARTNERS GP, L.L now owns 38,714,280 shares of Royalty Pharma plc, valued at $4,448,221 using the latest closing price.
ADAGE CAPITAL PARTNERS GP, L.L, the 10% Owner of Royalty Pharma plc, sale 7,200,000 shares at $43.92 during a trade that took place back on Dec 17, which means that ADAGE CAPITAL PARTNERS GP, L.L is holding 38,815,330 shares at $316,224,000 based on the most recent closing price.